Friday, 16 October 2026European Markets

NORSKE SKOG Stock Is 10% Down So Far On Thursday

Loading stream...

(VIANEWS) - Shares of NORSKE SKOG (Oslo Børs Benchmark Index_GI: NSKOG.OL) fell by a staggering 10.14% to kr46.50 at 14:37 EST on Thursday, after two sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI is rising 0.2% to kr1,207.20, following the last session's upward trend. This seems, as yet, a somewhat up trend exchanging session today.

NORSKE SKOG's last close was kr51.75, 34.37% under its 52-week high of kr78.85.

About NORSKE SKOG

Norske Skog ASA produces and sells newsprint and magazine papers. It operates in two segments, Publication Paper Europe, and Publication Paper Australasia. The company offers standard newsprint and other papers; and magazine paper comprising super calendared and lightweight coated magazine paper. Its products are primarily used in newspapers and magazines, catalogues, advertising materials, inserts/flyers, supplements, free-sheets, directories, direct mail, and book papers. The company operates in Norway, rest of Europe, North America, Australasia, Asia, and Africa. Norske Skog ASA was founded in 1962 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, NORSKE SKOG has a trailing twelve months EPS of kr26.19.

PE Ratio

NORSKE SKOG has a trailing twelve months price to earnings ratio of 1.78. Meaning, the purchaser of the share is investing kr1.78 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 56.89%.

More news about NORSKE SKOG (NSKOG.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com